Hitomi Morishima
3PUBLICATIONS
3CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (3)
Sort by Publication Date:
|Aug 28, 2021
Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study.Yukari Okubo, Hitomi Morishima, Richuan Zheng
|Jun 16, 2018
Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.Mamitaro Ohtsuki, Hiroshi Kubo, Hitomi Morishima
|Mar 24, 2018
Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.Shigetoshi Sano, Hiroshi Kubo, Hitomi Morishima
Pageof 1
